Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 10 of 10 for “"octreotide"”.

  1. Structure-activity relationship of octreotide analogues labeled with rhenium and technetium-99m

    The goal of this research is to cyclize octreotide analogues with ⁹⁹[supersript-m]Tc and ¹⁸⁶/¹⁸⁸Re radiometals to be used as diagnostic and therapeutic agents for neuroendocrine tumors, respectively. Several series of octreotide analogues that differ in their sequences, and/or coordination systems …

    missouri Repository record for Structure-activity relationship of octreotide analogues labeled with rhenium and technetium-99m (opens in a new tab)

  2. Ligand-Directed Aavp to Deliver A Therapeutic Transgene to Neuroendocrine Tumors of The Pancreas

    … of tumor necrosis factor (TNF). Our ligand, octreotide, is a somatostatin analog with specific affinity for SSTR2 that is currently used clinically for both imaging studies and the relief of symptoms associated with pancreatic neuroendocrine tumors. When displayed in AAVP, octreotide mediates …

    uthsc Repository record for Ligand-Directed Aavp to Deliver A Therapeutic Transgene to Neuroendocrine Tumors of The Pancreas (opens in a new tab)

  3. Part I: Effect of Nanomicelle Size on Trans-scleral Permeability of Dexamethasone and Part II: Strategies to Minimize Octreotide Acylation during Sustained Release from Biodegradable Polymers

    Our primary aim was to determine the effect of nanomicelle size on dexamethasone (DEX) transport across the sclera. Nanomicelles of various sizes were developed and characterized. Low molecular weight diblock co-polymers, mPEG₇₅₀-PCL₇₀₀ (DB1), mPEG₂₀₀₀-PCL₁₅₀₀ (DB2) and mPEG₅₀₀₀-PCL₄₀₀₀ (DB3) were …

    umkc Repository record for Part I: Effect of Nanomicelle Size on Trans-scleral Permeability of Dexamethasone and Part II: Strategies to Minimize Octreotide Acylation during Sustained Release from Biodegradable Polymers (opens in a new tab)

  4. Development of Random Triblock Copolymer Based Nanoparticulate Formulation for Sustained Release of Macromolecules/Biologics in Treatment of Posterior Segment Ocular Diseases

    … albumin, IgG Fab fragment, lysozyme, insulin and octreotide. Our results observed the effect of macromolecule molecular weight on drug loading and entrapment efficiency. In order to ensure sustained and prolonged release, nanoparticles were suspended in thermosensitive gel which acted as a …

    umkc Repository record for Development of Random Triblock Copolymer Based Nanoparticulate Formulation for Sustained Release of Macromolecules/Biologics in Treatment of Posterior Segment Ocular Diseases (opens in a new tab)

  5. Development of P(TMC)-Based Polymers for Sustained Delivery of Acid-Sensitive Drugs

    … Release of a representative peptide drug, octreotide, from the polymer was also studied. Increasing the HTMC content resulted in increased degradation, but complete degradation of the polymers was not achieved after 8 weeks, with degradation slowing considerably as HTMC content approached …

    queens Repository record for Development of P(TMC)-Based Polymers for Sustained Delivery of Acid-Sensitive Drugs (opens in a new tab)

  6. MR-tomografisches Langzeit-Follow-up GH-produzierender Hypophysenadenome unter Pegvisomant-Therapie. Eine prospektive Studie.

    … der Studie. Alle drei Patienten wurden zuvor mit Octreotide behandelt; keiner erhielt eine Radiotherapie. Die ANOVA zeigte keine signifikante Volumenänderung nach 24 Monaten. Die Rezidivrate dieser Studie unterscheidet sich nicht wesentlich von den Ergebnissen bisher veröffentlichter Studien zu …

    goettingen Repository record for MR-tomografisches Langzeit-Follow-up GH-produzierender Hypophysenadenome unter Pegvisomant-Therapie. Eine prospektive Studie. (opens in a new tab)

  7. Somatostatin Receptor 2 Regulation By C-Terminal Motifs and Pdz Domain Proteins

    … the drug target of somatostatin analogs such as octreotide, lanreotide, and pasireotide. Treatment with these agonists is the main medical approach to controlling excessive hormone secretion from neuroendocrine tumors. Activation of sst2 decreases hormone secretion by inhibiting cAMP production …

    uthsc Repository record for Somatostatin Receptor 2 Regulation By C-Terminal Motifs and Pdz Domain Proteins (opens in a new tab)

  8. Multimodality Somatostatin Analog For Fluorescence-Guided Surgery In Cancer

    … (NIRF) dye IR800 and targeting moiety Tyr-3-octreotide (TOC), producing MMC(IR800)-TOC. Here, we first examined the radiochemical and pharmacological properties of the dual-labeled analog. Subsequently, we evaluated the ability of the fluorescent somatostatin analog to selectively target …

    uthsc Repository record for Multimodality Somatostatin Analog For Fluorescence-Guided Surgery In Cancer (opens in a new tab)

  9. Nanomicelles And Liposomes For Improving Drug Delivery of Small Molecules And siRNA Therapeutic Agents

    … The PEGylated liposomes were targeted with Octreotide (OCT) peptide. OCT is an octapeptide analog of somatostatin (SST) growth hormone, having higher affinity for somatostatin receptors (SSTRs). These receptors are overexpressed on breast cancer cells. Optimized OCT-targeted Lcn2 siRNA …

    umkc Repository record for Nanomicelles And Liposomes For Improving Drug Delivery of Small Molecules And siRNA Therapeutic Agents (opens in a new tab)

  10. Long Term Ocular Drug Delivery with Novel Pentablock Copolymers; Part I: Composite Nanoformulation of Macromolecules For Back of the Eye Diseases, Part II: Dexamethasone Nanoparticle to Develop an In Vitro Model for Glaucoma

    … fragments). A wide variety of macromolecules (Octreotide, IgG-Fab, IgG-Fab‘ and IgG) with molecular weights ranging from 1 - 150 kDa have been used for this purpose. The kinematic viscosity of the copolymer solution was studied at different polymer concentration with different block arrangment. …

    umkc Repository record for Long Term Ocular Drug Delivery with Novel Pentablock Copolymers; Part I: Composite Nanoformulation of Macromolecules For Back of the Eye Diseases, Part II: Dexamethasone Nanoparticle to Develop an In Vitro Model for Glaucoma (opens in a new tab)